<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74968">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129673</url>
  </required_header>
  <id_info>
    <org_study_id>VS101-CS201</org_study_id>
    <nct_id>NCT02129673</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViSci Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViSci Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Slow release formulation of latanoprost is compared for safety and pressure-lowering
      efficacy with topically administration of commercially available latanoprost in patient with
      glaucoma and ocular hypertension
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>VS101 Insert Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS101 Insert Dose A placed under the conjunctiva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS101 Insert Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS101 Insert Dose B placed under the conjunctiva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS101 Insert Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS101 Insert Dose C placed under the conjunctiva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost 0.005% eye drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost 0.005% eye drops administered once daily on the eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS101 Insert Dose A</intervention_name>
    <description>Sustained release of latanoprost into the eye</description>
    <arm_group_label>VS101 Insert Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS101 Insert Dose B</intervention_name>
    <description>Sustained release of latanoprost into the eye</description>
    <arm_group_label>VS101 Insert Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS101 Insert Dose C</intervention_name>
    <description>Sustained release of latanoprost into the eye</description>
    <arm_group_label>VS101 Insert Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005% eye drops</intervention_name>
    <description>Latanoprost 0.005% eye drops administered once daily on the eye</description>
    <arm_group_label>Latanoprost 0.005% eye drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Open angle glaucoma or Ocular Hypertension

        Exclusion Criteria:

          -  uncontrolled medical conditions

          -  wearing of contact lenses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maital Ben-Hur</last_name>
    <email>maitalbenhur@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Speciality Eyecare Centre</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 31, 2016</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Intra-ocular pressure</keyword>
  <keyword>Slow Release</keyword>
  <keyword>Controlled release</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
